We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca’s and Amgen’s New Biologic Reduces Severe Asthma Attacks by 56 Percent
AstraZeneca’s and Amgen’s New Biologic Reduces Severe Asthma Attacks by 56 Percent
AstraZeneca’s and Amgen’s biologic drug tezepelumab reduced the rate of asthma attacks by 56 percent among patients with severe and uncontrolled forms of the condition, according to their just-released phase 3 trial results.